The results showed the peripheral blood in tumour‐bearing mice treated with anti‐PD1 antibody and then relapsed (anti‐PD1 antibody alone group in Model 1), manifested a compromised immune status (lower CD8+, lower CD4+ and lower GZMB+) before construction of Model 3 (Figure 5E). Here, PDCD1 is linked to neoplasm.